Merck Sharp + Dohme Corp.

Merck Sharp & Dohme LLC

Wenlang Fu

Amjad Ali

Sung-Sau So

John S Debenham

Dexi Yang

Daniel A Tatosian

Peter Nizner

John D Schreier

Dong Xiao

Robert R Wilkening

Phieng Siliphaivanh

Ping Liu

Andrew M Haidle

Izzat Tiedje Raheem

Rongze Kuang

Anthony K Ogawa

Charles A Lesburg

Catherine M White

Petr Vachal

Qinglin Pu

Lan Wei

Jacqueline D Hicks

Anthony Donofrio

Matthew A Larsen

Brandon D Cash

Zhiqiang Guo

Kenneth Ellsworth

Meng Yang

Tianying Jian

Yang Yu

Ming Wang

Zheng Tan

Jun Wang

Matthew Lombardo

Brett A Hopkins

Sulagna Sanyal

Xin Yan

Meredeth A Mcgowan

Ying-Duo Gao

Alan Hruza

Yeon-Hee Lim

Matthew J Lombardo

George Madalin Giambasu

Ning Qi

The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XI activation inhibitors.

Factor XI activation inhibitors

Described herein are compounds of Formula I or a pharmaceutically acceptable salt thereof. The compounds of Formula I act as IL4I1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for IL4I1-related diseases.

IL4I1 inhibitors and methods of use

Compounds of Formula I: I and their pharmaceutically acceptable salts are useful for the inhibition of HIV reverse transcriptase. The compounds may also be useful for the prophylaxis or treatment of infection by HIV and in the prophylaxis, delay in the onset or progression, and treatment of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antiviral agents, immunomodulators, antibiotics or vaccines. 

Antiviral oxime phosphoramide compounds

Growing community of inventors

Madison, NJ, United States of America

Wenlang Fu